A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia

Citation
L. Cifaldi et al., A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia, CANCER RES, 61(7), 2001, pp. 2809-2812
Citations number
20
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER RESEARCH
ISSN journal
0008-5472 → ACNP
Volume
61
Issue
7
Year of publication
2001
Pages
2809 - 2812
Database
ISI
SICI code
0008-5472(20010401)61:7<2809:ALNI1P>2.0.ZU;2-U
Abstract
With a slight asynchronous but consistent progression, all of the mammary g lands of female BALB/c mice transgenic for the transforming rat HER-2/neu o ncogene progress to atypical hyperplasia and to invasive carcinoma. Previou s studies have shown that chronic administration of interleukin (IL) 12 sta rted at the 2nd week of age hampers this progression because of its ability to inhibit tumor angiogenesis and activate a nonspecific immune response. Here we show that a similar inhibition is achieved when 7-week-old mice wit h fully blown atypical hyperplasia receive a weekly injection of 100 ng IL- 12 for 16 times. This lower-dose and later IL-12 administration induces hig h and sustained levels of serum IFN-gamma equivalent to those elicited by m ore frequent administrations. A lower-dose and less toxic treatment may thu s be envisaged as a possible option in the management of preneoplastic mamm ary lesions.